Viewing nowTerbinafine Tablet (Terbinafine Hydrochloride)
Terbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Kyongdong Pharmaceutical Co., Ltd.

MFDS item code 200102268 · Notified 2001.06.15 · Insurance code 648102110
Treatment of cutaneous fungal infections (e.g., tinea pedis and tinea corporis), onychomycosis, and tinea capitis
This medication is used in adults to treat tinea pedis, tinea corporis, tinea cruris, and onychomycosis caused by dermatophyte fungi. It is also used in children for the treatment of tinea capitis.
Adults Administer terbinafine 125 mg twice daily or 250 mg once daily. The treatment duration varies according to the condition, as follows: 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2–6 weeks Tinea corporis: 2–4 weeks Tinea cruris: 2–4 weeks 2) Onychomycosis Administer for 6 weeks to 3 months, usually. Infections of the fingernails or relatively small toenails, or treatment in younger patients, may require a shorter course of 3 months or less. A 3-month course is usually sufficient for toenail infections, although some patients may require 6 months or longer. Treatment may take longer in patients with slow nail growth. Patients with renal impairment Reduce the daily dose by 1/2 in patients with creatinine clearance less than 50 mL/min.
Administer to children 2 years and older. Administration is not recommended for children under 2 years because there is no experience with use in this age group. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of the infection, treatment should be regular and continued for the prescribed duration. Body weight less than 20 kg (under 5 years): Administer 62.5 mg once daily. Because experience with use is limited, decide whether to administer the drug after considering the benefits and risks of treatment. Body weight 20–40 kg (5–12 years): Administer 125 mg once daily. Body weight over 40 kg (over 12 years): Administer 250 mg once daily.
This medication is not recommended for patients with chronic liver disease or active liver disease. The patient's liver health should be assessed before prescribing, and regular liver function tests should be performed. If liver function worsens or liver-related symptoms appear, discontinue use immediately and consult a physician. Patients with blood disorders or severely impaired kidney function, children under 2 years of age, and nursing women should not use this medication. Elderly patients or children with low body weight, and patients with mildly impaired kidney function should use this medication with caution, and if severe skin reactions occur, they should discontinue use immediately. This medication can cause adverse reactions in various systems including the liver, blood, skin, muscles, digestive system, and nervous system, so any unusual symptoms should be reported to healthcare professionals immediately. Caution is needed while driving or operating machinery, as dizziness may occur. If taken with other medications, interactions may occur, so patients should inform their physician or pharmacist about any other medications being taken, as dosage adjustments may be necessary. Women who are pregnant or may become pregnant should use this medication with caution, and nursing mothers should discontinue breastfeeding while using this medication. In the case of overdose, symptoms such as headache, nausea, abdominal pain, and dizziness may occur; if these symptoms present, seek medical attention immediately. This medication should be kept out of reach of children and stored in a cool, dry place, avoiding direct sunlight.
Persistent nausea, decreased appetite, fatigue, vomiting, upper abdominal pain, jaundice, dark urine, loose stools, hepatobiliary failure, hepatitis, cholestasis, jaundice, rash, skin itching, fever, nausea, vomiting, decreased appetite, malaise, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, subcutaneous hemorrhage, leukopenia, anemia, rash, itching, photosensitivity reaction, mucocutaneous syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, blistering dermatitis, psoriatic rash, exacerbation of psoriasis, hair loss, arthralgia, myalgia, weakness, elevated CPK, rhabdomyolysis, hypotension, respiratory distress, chest tightness, urticaria, erythema, facial edema, lymphangitis, abdominal distension, dyspepsia, mild abdominal pain, diarrhea, discomfort in the upper abdomen, thirst, vomiting, glossitis, depression, anxiety, headache, dysgeusia, dizziness, drowsiness, paresthesia, decreased sensation, decreased attention, insomnia, elevated BUN, polyuria, visual disturbances, tinnitus, anaphylactic reaction, angioedema, systemic lupus erythematosus, elevated total cholesterol in the blood, elevated triglycerides, malaise, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, decreased vision, hearing loss, auditory impairment, vasculitis, permanent loss of smell, anosmia, hyposmia, drug rash with eosinophilia and systemic symptoms, pancreatitis, rhabdomyolysis, influenza-like illness, increased serum creatine phosphokinase, headache, nausea, upper abdominal pain, dizziness
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture from entering, and it is advisable to keep it at room temperature, away from extreme heat or cold.
White to pale yellow round tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowTerbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Kyongdong Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
GP Therapeutics Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Hutex Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Anguk Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Medica Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Gyeongnam Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Daehwa Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.